A notable focus of the US Food and Drug Administration during the tenure of Scott Gottlieb centered on the regulatory "gaming" tactics used by branded industry to prevent generic competition from reaching the market. But many of those tactics have now shifted to the commercial space, the former agency commissioner said.
Speaking at the Association for Accessible Medicines' GRx+Biosims 2019 meeting on 6 November, Gottlieb contended that innovators have mostly moved...







